NCT04650971View on ClinicalTrials.gov

"Study to Assess Safety, Tolerability and Reactogenicity of Vaccine UniFluVec After Two Intranasal Administrations in Healthy Volunteers"

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 29, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Influenza A
Interventions
BIOLOGICAL

UniFluVec

Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks

BIOLOGICAL

Placebo

Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks

Trial Locations (1)

Unknown

"Federal State Budgetary Institution Research Institute of Influenza of the Ministry of Health of the Russian Federation", Saint Petersburg

All Listed Sponsors
lead

Pharmenterprises Biotech LLC

OTHER

NCT04650971 - "Study to Assess Safety, Tolerability and Reactogenicity of Vaccine UniFluVec After Two Intranasal Administrations in Healthy Volunteers" | Biotech Hunter | Biotech Hunter